Immunovant has stopped development of its anti-FcRn antibody IMVT-1402 in cutaneous lupus erythematosus after the drug failed a phase 2 trial. The company said the midphase test did not succeed, though the specific efficacy or safety details were not disclosed in the announcement.
The move closes off one route to market for IMVT-1402, which had been positioned as a potential treatment for the skin-focused form of lupus. Anti-FcRn antibodies work by reducing circulating IgG antibodies, a mechanism being explored across several autoimmune conditions.
Immunovant's decision narrows its pipeline focus, though the company has not indicated whether IMVT-1402 will continue in other indications. The failed program underscores the difficulty of translating broad antibody-lowering approaches into positive results in lupus subtypes.